Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer

Go back to Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer
AGENUS (NASDAQ: AGEN) Delayed: 8.24 --0 (-0%)
Previous Close $8.24    52 Week High $7.49 
Open $8.24    52 Week Low $2.61 
Day High $8.24    P/E N/A 
Day Low $8.24    EPS $-1.10 
Volume 6,996